Member Info for Steadydanny

PCS. I'm no expert just follow my instincts re education and how I am me. So whose right?
Leave you with this and like to point out I'm a decent chap and respect your opinion.

You can know 90% of something but if you ignore the other 10% of something you don't know anything.
Best regards Steadydanny

PCS it's not big words. Basic DNA and RNA. That's why I'm invested. Atleast our 'products' if approved through normal testing protocol and not released for emergency use and have an ongoing test phase in the public domain that has no legal comeback, then I will stick with the science.

Hi Mafuta. I think I should have ended my point re Agile as per subscriptions better. I'm of the opinion that the subscriptions are because we will go our own way. Self funded.

PCS. What do you mean? A treatment required post vaccinations and boosters? So what is the point of the previous given initial and latter efficacy rates? Will passports require vaccine certification and treatments in the future?I think you have missed the point re cytokine storms and cytotoxicity and how they are related to the degradation of tyrosine that removes naturally degrading cytosine that is toxic and causes cytotoxicity and cytokine storms and how they may be caused. Sareum are effectively dealing with the storms and cytotoxicity re imo 1801 1802 and new and improved 1802.

We noted dec 2020 and said 6 months
Quote

SDC-1801 – Covid-19 studies

The UKRI-funded Covid-19 research project for SDC-1801 is expected to complete on schedule with the experimental phases finishing in June and the data analysis to complete shortly thereafter. The Company will provide a further update once the relevant data are available.  

As noted in the Interim Results, initial results from this research are encouraging and demonstrate that SDC-1801 reduces the levels of cytokines associated with Acute Respiratory Distress Syndrome in human lung cells infected with SARS-CoV-2.

If the completed studies are successful, the Company plans to explore the possibility for further UK government funding from the recently launched AGILE clinical development platform, which has been established to fund Phase 1 trials and fast-track the development of potentially ground-breaking Covid-19 treatments. These activities are expected to run in parallel with the broader SDC-1801 development...
Then Mr Reader says
Dr John Reader, CSO of Sareum, commented:

“The results from our Covid-19 research project are very encouraging and provide clear evidence of the potential of SDC-1801 to reduce the excessive inflammatory response seen in severe Covid-19. We are keen to progress this project to the next stage and will now explore our options to find the best way to fund these next steps. This could include the UK government’s AGILE clinical development platform, which was established to fund Phase 1 trials and fast-track the development of potentially ground-breaking Covid-19 treatments. These activities are expected to run in parallel with the broader SDC-1801 development plan targeting autoimmune diseases. We look forward to providing updates on our progress as we reach key milestones in the development of SDC-1801.”

The Grant for the project was awarded to Sareum through the Innovate UK Sustainable Innovation Fund for projects that address and mitigate the health, social, cultural and environmental impacts of the Covid-19 outbreak.
Given all the talk of Agile anyone think it a little bit coincidental the following RNSs were subscriptions..aka 'could include Agile.'
Just a muse.
I might go for an amuse bouche

Stoney a UKIPO requires a separate patent application to be given credence in USA.

Evening HBD. Greatly appreciate your response.
Even though it is to be granted I believe 26th Oct I draw this point to the extract
Therefore, when the patent examiner “allows” your patent application, you do not let it “grant.” That would start your 17-year term. Rather, you file a “continuation” to keep it “underwater” or “pending.” During this time, competitors develop and adopt the technology.
So if we get a RNS Update that stipulates we file a continuation or pending print to said date.....then I make the assumption we are the goose laying the eggs per sei.
If it continues to granted that means we are poking our heads above the pharma parapet and saying who wants a piece of this publicly.
However, the latter thought diminishes the reason d etre of a submarine patent. Imo.
As you mentioned cloak and dagger. Yes I think it's us saying to license holders or interested bodies...pay up or move on.
Enjoy your posts HBD.

I'm no expert on patents but did a bit of research. From what I understand we don't have to release its details as any company that uses is in effect paying royalties if their technology advancement finds a future use to said updated patent. Which can remain 'underwater. So this is a copy re submarine patents
The key difference between the pre-1995 17-year patent term and the current 20-year patent term is the start date. Currently, once you file a patent application the clock is ticking down on the 20 years. There are provisions to add some time to that 20-year calculation. These provisions mostly account for government delays like slow patent examination or hold-ups in the FDA approval process.

However, the 17-year patent term only starts when the patent actually issues. Therefore, when the patent examiner “allows” your patent application, you do not let it “grant.” That would start your 17-year term. Rather, you file a “continuation” to keep it “underwater” or “pending.” During this time, competitors develop and adopt the technology. Once the industry embraces the technology, you finally allow your submarine patent to “surface.” This starts your 17-year patent term. However, now the technology is ubiquitous and you have greater leverage to force a settlement or payout.

And this our October 1802 patent update
The patent (US 11,154,539) will grant on 26 October 2021 and will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat cancer selected from pancreatic, colorectal and kidney cancers, melanoma, and B-cell lymphoma by inhibiting TYK2 kinase. This programme is in preclinical development.
So really love some thoughts re submarine patent. Have we got the patent for something that will be exponential in all big pharmas wanting a piece of it and to develop at their own cost and direction? Which we would act as advisors but due to NDAs cannot reveal their direction? But take multiple licences and royalties?
Anyhow just a muse.
Best regards Steadydanny

Looks like New GSK won't happen until mid year 2022 . ...so I suspect we release ongoing trial timetable for 1802 soon. Pound to a penny it's locked and loaded. And maybe just maybe GSK buy in to show the institutions and shareholders they have a library of ipr to split the vaccine and research part to keep them happy so as not to feck their sp up!?
Out of curiosity anyone know of any ipr to the levels we have that could affect a mc worth for a major pharmaceutical like we have that certain pharmas like to be seen as the golden goose on undertaking preclinical advancements?
We have way beyond any small pharma of ipr that sings potential that I have researched.

Have some balls. We have great ipr!? Yes or no?

You are missing the point Alex. Not being rude. A split is happening..that's a known. Vaccine on one side...efficacy %....not great...new gsk investment...pound to a penny they are required new ipr. Getting very very boring. For a company listed not to see what you need is a joke. You all just sat thinking gsk going to look after you?
They are spitting. Major companies looking at a buy out...unless they find worthy companies with great ipr.
I assume u are all bored and made your gains. Wake up

Nice Post Hbd.
For the record if I was a HNWI would you advise post Elliot report if I should chuck a million and other investor's into sareum similar amounts?
Yep they ain't investing for a loss.
When we catch up I like a cheeky Syrah.
News incoming by end of month.
Investor's sat on shares. Wombles tried 3 times this year. Positive news followed. I'm all up for a link up.

Ndr. I think those who have bought have bought who are sitting back. The sells are manipulation sells. They want our shares. Last rattle before news. Imo.

ndr here is a gsk update today. They are splitting.
Thoth called certain investors potentially.
Alliance News) - GlaxoSmithKline PLC's consumer unit is drawing interest from private equity firms in what could lead to the biggest buyout of all time, Bloomberg reported Tuesday, citing people with knowledge of the matter.

According to Bloomberg, Advent International, CVC Capital Partners and KKR & Co were among potential suitors evaluating the business. Further, Blackstone, Carlyle Group and Permira were also seen as likely suitors for the unit, which could be valued at GBP40 billion.

They need ipr. We have been quiet. Our ipr fits investment requirements. Institutions are the money.
I've had my discussions with Thoth. Albeit I had differences. Any lth who is willing to discuss medium/short term holders opinions is worth a moment of thought.
I'm happy here.
Anyone got one negative point here which hasn't got a respectfully considerate and factual response to?

Thoth. Just been researching. Re GSK ...don't ask but possibly biggest takeover of all time. But you came up re post June 2021 re CVC capital. And pill prices. Re the point you made back then I'm in awe. If your muse back then that has seen gravitas today via a news outlet I will shower you in wotsits.

Mafuta something is afoot. Have a look at GSK RNSs today. Directors deals. They are definitely wanting to divide vaccine and research. As WIP said they need to keep institutions etc happy. Not a happy ship there.
Massive money chest though for new gsk!
I feel certain we hear something when the split occurs. Not to disregard Elliot have said they need top notch Directors with a scientific background. They invested billions earlier this year.
Tick tock.

Firstly re does anyone work given time posting on here. Well what is that of anyone's business. And from what I can ascertain from Sunday night posts there are a darn more lot of people reading the contributions on here than post, more likely catching up on a Sunday evening as they have other thingsto do. I enjoy the links and the potential dot joining.
Re sareum silence. Well we have had news and more news is inevitable. Whatever it is. But we definitely tick a lot of boxes for pharma to want to share our ipr. I mean the board are putting a plan together re progressing trials for 1802 amongst other work I'm sure...discussions.
Final bit re my GSK drumbeat is that the incoming planned split with New GSK and as was mooted by insiders they will probably have to pay top price for preclinical (and other) molecules/research.
So would we release news first or wait for GSK to do the split first (if we are involved) and then a joint RNS advising both parties shareholders that promising research and trials lie ahead?
That's what I think.

I suggest you read our website first Mike. It would atleast show you have a slither of genuine interest here.
Here's a taster re costs...its on The Strategy page
Our strategy

Sareum’s strategy is to develop programmes to late preclinical or early clinical stages to take advantage of the higher asset values associated with licensing programmes at these stages.

ApproachBenefit
Pursue multiple programmes
Increase potential success rate
Mitigate development risk
Seek collaboration partners
Spread financial cost and risk
Introduce specialist research expertise

Develop programmes to pre-clinical/
early clinical development

Minimise ongoing development risk
Move up value chain
Potential for higher deal values

It's really rather genius. Plenty more on the website. Eduction is a form of enlightenment.
And then there was light.....and you could see for frickin miles....
Most welcome
Steadydanny

OK just shot my load on gsk. Told them about our great research here. If they are not just independent purchasers then the advisors will look at posts here and the research by posters for why I am here. You know who you are!
Putting my bits out there.
If they spend 5 minutes reading the progress I think they will get it.
Hoped more of you would have made our ipr potential relevant to those that trade without understanding real investment.

But you need new ipr for New GSK. Where is it going to come from? You need new scientific proven directors! Where are you going to get that? Getting a bit boring now. So obvious re lupus, cytokinase inhibitors (that's the money shot) . Catch up when you are ready. A big fish suffocating needs small fish with ipr that will keep you swimming and possibly leaping. Not hard to follow. Possibly the best bb on lse awaits you. Great info. Never derogatory. Just Great knowledgeable posts. But up to you. I feel like a minnow tickling a salmon.